Lytix Biopharma presents first quarter 2023 results
Oslo, 11 May 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its first quarter 2023 results – New class of immunotherapy.“Lytix is fast approaching an important milestone, as we now are looking forward to completing recruitment in our ATLAS-IT-05 study this summer and deliver the first interim report from this study before the end of the year. At the same time, we are encouraged by seeing our partner Verrica Pharmaceuticals continue to make progress in their Phase II study, now running through the